| Literature DB >> 34160770 |
Yue-Yue Ding1, Yan Ren2, Jie Qin1, Guang-Hui Qian3, Yun-Jia Tang1, Ye Chen1, Xuan Li1, Lei Xu1, Chun-Hong Qiao4, Ling Sun1, Hai-Tao Lv5.
Abstract
BACKGROUND: The aim of this study is to explore the characteristics of Kawasaki disease (KD) and concurrent pathogens due to a stay-at-home isolation policy during coronavirus disease 2019 (COVID-19) epidemic.Entities:
Keywords: COVID-19; Concurrent pathogens; Isolation; Kawasaki disease; Mycoplasma pneumoniae
Mesh:
Year: 2021 PMID: 34160770 PMCID: PMC8219783 DOI: 10.1007/s12519-021-00431-2
Source DB: PubMed Journal: World J Pediatr Impact factor: 2.764
Fig. 1The incidences of Kawasaki disease (KD) for inpatients and outpatients between February 1st to April 30th from 2015 to 2020. a The histogram shows the incidences of KD for inpatients between February 1st to April 30th from 2015 to 2020; b the histogram shows the incidences of KD for outpatients between February 1st and April 30th from 2015 to 2020; c the incidence of KD for inpatients and outpatients in each year are shown in percentage with 95% confidence interval
Clinical and laboratory features of Kawasaki disease under the pandemic of COVID-19 or not in recent 6 years
| Variables | Group 1 ( | Group 2 ( | |
|---|---|---|---|
| Male, | 281 (57.0) | 63 (58.9) | 0.80 |
| Age (mon), median (range) | 21 (1–159) | 22 (2–111) | 0.50 |
| < 6, | 43 (8.7) | 8 (7.5) | 0.80 |
| 6–12, | 66 (13.4) | 12 (11.2) | 0.70 |
| 12–36, | 251 (50.9) | 56 (52.3) | 0.90 |
| 36–60, | 73 (14.8) | 21 (19.3) | 0.27 |
| ≥ 60, | 60 (12.2) | 10 (9.4) | 0.51 |
| Conjunctival congestion, | 426 (86.4) | 88 (82.2) | 0.29 |
| Oral mucosal changes, | 426 (86.4) | 77 (72.0) | |
| Strawberry tongue, | 328 (66.5) | 45 (42.1) | |
| Rash, | 353 (71.6) | 85 (80.2) | 0.07 |
| Edema of extremities, | 208 (42.2) | 45 (42.1) | 1.00 |
| Desquamation of the fingertips, | 156 (31.6) | 13 (12.2) | |
| Desquamation of the perineal region, | 120 (24.3) | 19 (17.8) | 0.17 |
| Cervical lymphadenopathy, | 445 (90.3) | 79 (73.8) | |
| Changes at BCG site, | 86 (17.4) | 16 (15.0) | 0.57 |
| IVIG responders, | 381 (77.3) | 84 (78.5) | 0.90 |
| Complete KD, | 407 (82.6) | 91 (85.1) | 0.67 |
| Steroid regimen intravenous injection, | 38 (7.7) | 7 (6.5) | 0.84 |
| CAL or not CAL, | 83 (17.4) | 19 (17.8) | 0.90 |
| KD shock syndrome, | 0 (0) | 0 (0) | NA |
| Macrophage activation syndrome (KD-MAS), | 3 (0.6) | 2 (1.9) | 0.10 |
| White cell count (× 109/L), mean ± SD | 15.3 ± 6.1 | 14.6 ± 5.4 | 0.30 |
| Neutrophils%, mean ± SD | 59.9 ± 21.9 | 65.3 ± 15.5 | |
| Hemoglobin (g/L), mean ± SD | 108.7 ± 12.7 | 110.2 ± 11.5 | 0.30 |
| Platelet count (× 109/L), mean ± SD | 375.1 ± 136.4 | 363.4 ± 133.3 | 0.40 |
| Serum albumin (g/L), mean ± SD | 39.0 ± 14.4 | 40.6 ± 3.6 | 0.30 |
| CRP (mg/L), mean ± SD | 81.1 ± 59.4 | 74.8 ± 49.8 | 0.30 |
| ESR (mm/h), mean ± SD | 38.0 ± 24.7 | 39.3 ± 22.3 | 0.60 |
| ALT (U/L), mean ± SD | 50.4 ± 72.1 | 60.8 ± 77.1 | 0.20 |
| AST (U/L), mean ± SD | 54.8 ± 81.1 | 61.2 ± 92.7 | 0.50 |
| LDH (mmol/L), mean ± SD | 401.7 ± 145.4 | 400.8 ± 148.2 | 1.00 |
COVID-19 coronavirus disease 2019, KD Kawasaki disease, IVIG intravenous immunoglobulin, CAL coronary artery lesions, CRP C-reactive protein, ESR erythrocyte sedimentation rate, ALT alanine aminotransferase, AST aspartate aminotransferase, LDH lactate dehydrogenase, SD standard deviation, NA not available. Bold letters indicating significance
Fig. 2Characteristics of virus- and MP-infected patients for the two groups in the years of 2015–2020. a The detection and positive ratios of virus- and MP-infection of KD patients for groups of 1 and 2 from 2015 to 2020 are demonstrated by Wenn graphs. Values are n (%); *, † and ‡ indicate P < 0.05, P < 0.01 and P < 0.001, respectively; b bar graph shows the detailed number of virus-infected patients in each year from 2015 to 2020, MP Mycoplasma pneumoniae, N neutrophils, CP chlamydia pneumoniae, EBV Epstein-Barr virus, CMV cytomegalovirus, COX coxsackievirus, RV rotavirus, Inf A, B influenza virus A & B, Pinf 1, 2, 3 parainfluenza virus 1, 2 & 3, RSV respiratory syncytial virus, ADV adenovirus
Etiological detection in Kawasaki disease and outpatient among February to April in 2020
| Variables | Non-KD group ( | KD group ( | OR (95% CI) | |
|---|---|---|---|---|
| Male, | 2674 (57.6) | 63 (58.9) | 0.80 | NA |
| Age (mon), median (range) | 51 (1–216) | 22 (2–111) | NA | |
| MP+, | 778 (16.8) | 34 (34.7) | 2.6 (1.73–4.03) | |
| Virus+, | 274 (5.9) | 4 (5.3) | 1.00 | 0.9 (0.32–2.44) |
KD Kawasaki disease, MP Mycoplasma pneumonia. OR odds ratio, CI confidence interval, NA not available. Bold letters indicating significance
The positive of Mycoplasma pneumonia detection in Kawasaki disease of various age groups from 2015 to 2020
| Age | Group 1 (2015–2019) | Group 2 (2020) | |||
|---|---|---|---|---|---|
| Positive number | Detection number | Positive number | Detection number | ||
| Total number, | 81 (19.3) | 420 (100) | 34 (34.7) | 98 (100) | NA |
| < 12 mon, | 14 (13.1) | 107 (25.5) | 5 (23.8) | 21 (21.4) | |
| 12–36 mon, | 36 (17.6) | 204 (48.6) | 19 (37.3) | 51 (52.0) | |
| 36–60 mon, | 16 (27.6) | 58 (13.8) | 6 (35.4) | 17 (17.3) | 0.38 |
| > 60 mon, | 15 (29.4) | 51 (12.1) | 4 (44.4) | 9 (9.2) | 0.56 |
NA not available. Bold letters indicating significance